Functional evidence for a role of combined CDKN2A (p16-p14(ARF))/CDKN2B [p15) gene inactivation in malignant gliomas

Acta Neuropathologica

Volumn 98, Issue 5, 1999, Pages 444-452

  Simon, Matthias ^a   Köster, Gertraud ^a   Menon, Anil G ^b   Schramm, Johannes ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Glioblastoma; p14(ARF); p15; p16; Tetracycline controlled operator

Indexed keywords

CYCLIN DEPENDENT KINASE; PROTEIN P15; PROTEIN P16; TETRACYCLINE;

ALTERNATIVE RNA SPLICING; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CHROMOSOME 9P; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; BRAIN NEOPLASMS; DNA, NEOPLASM; GENE SILENCING; GENES, P16; GLIOMA; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PROTEINS; TETRACYCLINE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 0344199413     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004010051107     Document Type: Article

References (53)

1. Arap W, Nishikawa R, Furnari FB, Cavenee WK, Su Huang H-J (1995) Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 55: 1351-1354
2. Arap W, Knudsen E, Sewell DA, Sidransky D, Wang JYJ, Su Huang H-J, Cavenee WK (1997) Functional analysis of wild-type and malignant glioma derived CDKN2Aβ alleles: evidence for an RB-independent growth suppressive pathway. Oncogene 15: 2013-2020
3. Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, Vousden KH (1998) p14ARF links the tumour suppressors RB and p53. Nature 395: 124-125
4. Batova A, Diccianni MB, Yu JC, Nobori T, Link MP, Pullen J, Yu AL (1997) Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res 57: 832-836
5. Beroud C, Soussi T (1998) p53 gene mutation: software and database. Nucleic Acids Res 26: 200-204
6. Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H (1997) Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol 94: 303-309
7. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, Riet P van der, Blaugrund JE, Sidransky D (1994) Rates of p 16 (MTS1) mutations in primary tumors with 9p loss. Science 265: 415-416
8. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano F, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, Sidransky D (1995) Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11: 210-212
9. Costello JF, Berger MS, Su Huang H-J, Cavenee WK (1996) Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 56:2405-2410
10. Duro D, Bernard O, Della Valle V, Berger R, Larsen C-L (1995) A new type of p16INK4a/MTS1 gene transcript expressed in B-cell malignancies. Oncogene 11: 21-29
11. Fang X, Jin X, Xu H-J, Peng H-Q, Hogg D, Roth JA, Yu Y, Xu F, Bast RC Jr, Mills GB (1998) Expression of p16 induces transcriptional downregulation of the RB gene. Oncogene 16: 1-8
12. Fueyo J, Gomez-Manzano C, Yung WKA, Clayman GL, Liu T-J, Bruner J, Levin VA, Kyritsis AP (1996) Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 12: 103-110
13. Fueyo J, Gomez-Manzano C, Bruner J, Saito Y, Zhang B, Zhang W, Levin VA, Yung WKA, Kyritsis AP (1996) Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene 13: 1615-1619
14. Gossen M, Bujard H (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89: 5547-5551
15. Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera AG, Xiong Y (1994) Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRB function. Genes Dev 8: 2939-2952
16. Haber DA (1997) Splicing into senescence: the curious case of p16 and p19ARF. Cell 91: 555-558
17. Hannon GJ, Beach D (1994) p15INK4B is a potential effector of TGFβ-induced cell cycle arrest. Nature 371: 257-261
18. He J, Reifenberger G, Liu L, Collins VP, James CD (1994) Analysis of glioma cell lines for amplification and overexpression of MDM2. Genes Chromosomes Cancer 11: 91-96
19. Herman JG, Jen J, Merlo A, Baylin SB (1996) Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 56: 722-727
20. Herman JG, Civin CI, Issa J-PJ, Collector MI, Sharkis SJ, Baylin SB (1997) Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57: 837-841
21. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC (1994) Germline p16 mutations in familial melanoma. Nat Genet 8: 15-21
22. Iravani M, Dhat R, Price CM (1997) Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15INK4B) in childhood acute lymphoblastic leukemia. Oncogene 15: 2609-2614
23. Izumoto S, Arita N, Ohnishi T, Hiraga S, Taki T, Hayakawa T (1995) Homozygous deletions of p16INK4A/MTS1 and p15INK4B/MTS2 genes in glioma cells and primary glioma tissues. Cancer Lett 97: 241-247
24. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JKV, Kanzler KW, Vogelstein B (1994) Deletion of p16 and p15 genes in brain tumors. Cancer Res 54: 6353-6358
25. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day III RS, Johnson BE, Skolnick MH (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440
26. Kamb A, Shattuck-Eidens D, Eeles R, et al (1994) Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8: 22-26
27. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr C (1998) Tumor suppression at the mouse INK4A locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-659
28. Li Y, Nichols MA, Shay JW, Xiong Y (1994) Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRB. Cancer Res 54: 6078-6082
29. Li Y-J, Hoang-Xuan K, Delattre J-Y, Poisson M, Thomas G, Hamelin R (1995) Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene 11: 597-600
30. Liggett WH Jr, Sewell DA, Rocco J, Ahrendt SA, Koch W, Sidransky D (1996) p16 and p16β are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res 56: 4119-4123
31. Lukas J, Müller H, Bartkova J, Spitkovsky D, Kjerulff AA, Strauss M, Bartek J (1994) DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J Cell Biol 125: 625-638
32. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D (1995) A novel p16INK4A transcript. Cancer Res 55: 2995-2997
33. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D (1995) 5′CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1:686-692
34. Morgenstern JP, Land H (1990) Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 18: 3587-3596
35. Moulton T, Samara G, Chung W-Y, Yuan L, Desai R, Sisti M, Bruce J, Tycko B (1995) MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 146: 613-619
36. Okamoto A, Hussain SP, Hagiwara K, Spillare EA, Rusin MR, Demetrick DJ, Serrano M, Hannon GJ, Shiseki M, Zariwala M, Xiong Y, Beach DH, Yokota J, Harris CC (1995) Mutations in the p16INK4A/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 55: 1448-1451
37. Pollock PM, Pearson JV, Hayward NK (1996) Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer 15: 77-86
38. Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee H-W, Cordon-Cardo C, DePinho RA (1998) The INK4A tumor suppressor gene product, p19ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723
39. Quelle DE, Zindy F, Ashmun RA, Sherr CJ (1995) Alternative reading frames of the INK4A tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000
40. Quelle DE, Cheng M, Ashmun RA, Sherr CJ (1997) Cancer-associated mutations at the INK4A locus cancel cell cycle arrest by p16INK4A but not the alternative reading frame protein p19ARF. Proc Natl Acad Sci USA 94: 669-673
41. Reymond A, Brent R (1995) p16 proteins from melanomaprone families are deficient in binding to CDK4. Oncogene 11: 1173-1178
42. Schmidt EE, Ichimura K, Messerle KR, Goike HM, Collins VP (1997) Infrequent methylation of CDKN2A (MTS1/p16) and rare mutations of both CDKN2A and CDKN2B (MTS2/p15) in primary astrocytic tumours. Br J Cancer 75: 2-8
43. Serrano M, Lee HW, Chin L, Cordon-Cardo C, Beach D, De-Pinho RA (1996) Role of the INK4A locus in tumor suppression and cell mortality. Cell 85: 27-37
44. Sherr C (1996) Cancer cell cycles. Science 274: 1672-1677
45. Smith-Sørensen B, Hovig E (1996) CDKN2A (p16INK4A) somatic and germline mutations. Hum Mutat 7: 294-303
46. Spruck CH III, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin M-F, Gonzales F, Tsai YC, Jones PA (1994) p16 gene in uncultured tumours. Nature 370: 183-184
47. Stone S, Dayananth P, Jiang P, Weaver-Feldhaus JM, Tavtigian SV, Cannon-Albright L, Kamb A (1995) Genomic structure, expression and mutational analysis of the p15 (MTS2) gene. Oncogene 11: 987-991
48. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A (1995) Complex structure and regulation of the p16 (MTS1) locus. Cancer Res 55: 2988-2994
49. Tenan M, Benedetti S, Finocchiaro G (1995) Deletion and transfection analysis of the p15/MTS2 gene in malignant gliomas. Biochem Biophys Res Commun 217: 195-202
50. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJ, Friedmann T, De Tribolet N, Cavenee WK (1994) Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 54: 649-652
51. Yang R, Gombart AF, Serrano M, Koeffler HP (1995) Mutational effects on the p16INK4A tumor suppressor protein. Cancer Res 55: 2503-2506
52. Yoshida S, Todoroki T, Ichikawa Y, Hanai S, Suzuki H, Hori M, Fukao K, Miwa M, Uchida K (1995) Mutations of p16INK4A/CDKN2 and p15/MTS2 genes in biliary tract cancers. Cancer Res 55: 2756-2760
53. Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4A locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734